Clinical Trials Browser

ostarine × Clear all

NCT01616758 2024-03-08

Phase II Study of GTx024 in Women With Metastatic Breast Cancer

Phase 2 Terminated

22 enrolled 5 charts

Breast Neoplasms

NCT02746328 2024-02-26

Add-on Study for Protocol G200802 (NCT02463032): Effect of GTx-024 on Maximal Neuromuscular Function and Lean Body Mass

Phase 2 Withdrawn

ER+ and AR+ Breast Cancer

NCT05065411 2024-02-26

VERU-024

Phase 3 Terminated

Breast Neoplasms

NCT04869943 2024-01-26

ARTEST

Phase 3 Terminated

Breast Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT02463032 2020-12-09

Efficacy and Safety of GTx-024 in Patients With Estrogen Receptor (ER)+/Androgen Receptor (AR)+ Breast Cancer

Phase 2 Completed

136 enrolled 14 charts

ER+ and AR+ Breast Cancer

NCT02368691 2020-11-18

Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)

Phase 2 Terminated

32 enrolled 12 charts

Triple Negative Breast Neoplasms

NCT01355497 2020-11-09

Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum

Phase 3 Completed

330 enrolled 7 charts

Carcinoma, Non-Small-Cell Lung, Muscular Atrophy

NCT00467844 2014-07-11

Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.

Phase 2 Completed

159 enrolled 11 charts

GastrointestinalLymphoidThoracic

Cachexia, Carcinoma, Non-Small-Cell Lung, Lymphoma, Non-Hodgkin, Muscular Atrophy, Colorectal Neoplasms